title: Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region.
abstract: BACKGROUND
  Monitoring hepatitis C virus (HCV) antibodies (anti-HCV) in long-term dialysis patients is an important issue of public health. The aim of the study is to analyze the prevalence, seroconversion rate, and impact of HCV-positive serological test results on survival.
  
  
  METHODS
  We studied 6,412 patients starting long-term dialysis therapy reported to Lazio Dialysis Registry (Italy) between 1995 and 2003. HCV serological status was assessed by using second- or third-generation assays. Patients who were seronegative at the beginning of a period who became seropositive at the end of the same period are defined as seroconverters.
  
  
  RESULTS
  In 1995 to 2003, the overall prevalence of anti-HCV among long-term dialysis patients decreased from 30.6% to 15.1%; we did not observe a decrease in prevalence of anti-HCV in those starting dialysis treatment. After a decrease in the first year, HCV seroconversion rates remained stable at approximately 2 cases/100 person-years. Survival at 9 years was lower for both HCV seroconverters and those already anti-HCV positive at dialysis therapy initiation compared with HCV-negative subjects (log-rank test, P < 0.001). Results of a multiple Cox model showed that subjects who were or became anti-HCV positive had a hazard ratio of 1.29 (95% confidence interval, 1.15 to 1.44) compared with HCV-negative patients.
  
  
  CONCLUSIONS
  We did not observe a significant decrease in HCV seroconversion rates in 1995 to 2003. The overall decrease in anti-HCV prevalence could be related to the lower survival probability for both HCV seroconverters and those already HCV positive at long-term dialysis therapy initiation compared with HCV-negative subjects. Our findings confirm that additional efforts should be made to minimize the risk for HCV infection before and during long-term dialysis treatment.
authors.affiliation: Agency for Public Health of Lazio Region, Rome, Italy. dinapoli@asplazio.it
authors.forename: Anteo
authors.initials: A
authors.lastname: Di Napoli
authors.forename: Patrizio
authors.initials: P
authors.lastname: Pezzotti
authors.forename: Domenico
authors.initials: D
authors.lastname: Di Lallo
authors.forename: Nicola
authors.initials: N
authors.lastname: Petrosillo
authors.forename: Claudia
authors.initials: C
authors.lastname: Trivelloni
authors.forename: Salvatore
authors.initials: S
authors.lastname: Di Giulio
mesh_terms: D000368:Aged; D005260:Female; D016174:Hepacivirus; D006526:Hepatitis C / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007558:Italy / Q000453:epidemiology; D007674:Kidney Diseases / Q000628:therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016016:Proportional Hazards Models; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D018937:Hepatitis C Antibodies